Clinical Trial Update: A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PF-03446962 plus best supportive care versus placebo plus best supportive care in recurrent hepatocellular carcinoma; the trial was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PF-03446962 (PF-03446962)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: TERMINATED | Results posted: 2015-06-29